Skip to main content

Table 1 Currently open phase I/II clinical trials for lung cancer

From: Emerging therapeutic agents for lung cancer

Drug class Drug Mechanism of action Clinical trials (phase) Study design Disease
Tumor epigenetics Entinostat Histone deacetylase (HDAC) inhibitor NCT02437136 (1/2) Combination NSCLC
HBI-8000 NCT02718066 (1/2) Combination NSCLC
ACY 241 NCT02635061 (1) Combination NSCLC
Epacadostat NCT02298153 (1) Combination NSCLC
Mocentinostat NCT02805660 (1/2) Combination NSCLC
CC-486 DNA hypomethylation NCT02250326 (2) Combination NSCLC
Azacitidine NCT02009436 (1) Monotherapy NSCLC
RRX-001 DNA methylation, histone deacetylation, and lysine demethylation NCT02489903 (2) Monotherapy NSCLC
Tumor metabolism Ethaselen Thioredoxin reductase NCT02166242 (1) Monotherapy NSCLC
TAS-114 dUTPase NCT02855125 (2) Combination NSCLC
ADI-PEG 20 Pegylated arginine deiminase NCT02029690 (1) Combination NSCLC
CCT245737 Checkpoint kinase 1 NCT02797977 (1) Combination NSCLC/SCLC
LY2606368 NCT02860780 (1) Combination NSCLC/SCLC
CB-839 Glutaminase NCT02771626 (1/2) Combination NSCLC
Immunotherapy Cancer vaccines
CV301 Tumor peptide vaccine NCT02840994 (1/2) Combination NSCLC
TG4010 NCT02823990 (2) Combination NSCLC
Gemogenovatucel-T NCT02639234 (2) Combination NSCLC
CMB305 NCT02387125 (1) Monotherapy NSCLC
DC-CIK Dendritic cell vaccine NCT02688686 (1/2) Monotherapy NSCLC
DCVAC/LUCA NCT02470468 (1/2) Monotherapy NSCLC
AGS-003-LNG NCT02662634 (2) Monotherapy NSCLC
JNJ-64041757 Listeria vaccine NCT02592967 (1) Monotherapy NSCLC
ADXS11-001 NCT02531854 (2) Combination NSCLC
DSP-7888 WT1 vaccine NCT02498665 (1) Monotherapy NSCLC
S-588410 (HLA)-a*2402-restricted epitope peptides NCT02410369 (2) Monotherapy NSCLC
AD-MAGEA3 and MG1-MAGEA3 MAGE-A3-expressing maraba virus NCT02879760 (1/2) Monotherapy NSCLC
L-DOS47 Immunoconjugate NCT02340208 (1/2) Monotherapy NSCLC
NCT02309892 (1) Monotherapy NSCLC
DRibbles NCT01909752 (2) Monotherapy NSCLC
Checkpoint inhibitors
Enoblituzumab (MGA271) B7-H3 antibody NCT02475213 (1) Combination NSCLC
NCT01391143 (1) Monotherapy NSCLC
MGD009 NCT02628535 (1) Monotherapy NSCLC
CM-24 CEACAM1 antibody NCT02346955 (1) Combination NSCLC
Indoximod Indoleamine 2,3-dioxygenase (IDO) inhibitor NCT02460367 (1/2) Combination NSCLC
AMG 820 Colony-stimulating factor 1 receptor (CSF1R) NCT02713529 (1/2) Combination NSCLC
PF-05082566 4-1BB agonist NCT02315066 (1) Combination NSCLC/SCLC
PBF-509 Adenosine A2a NCT02403193 (1/2) Combination NSCLC
CPI-444 NCT02655822 (1) Combination NSCLC
PF-04518600 Anti-OX40 mAb NCT02315066 (1) Combination NSCLC/SCLC
JNJ-61610588 Anti-VISTA NCT02671955 (1) Monotherapy NSCLC/SCLC
PDR001 Anti-PD1 NCT02460224 (1/2) Combination NSCLC/SCLC
CA-170 Oral PDL1/PDL2/VISTA inhibitor NCT02812875 (1) Monotherapy NSCLC/SCLC
Avelumab PD- L1 inhibitor NCT02584634 (2) Combination NSCLC
Varlilumab Anti-CR27 mAb NCT02335918 (1) Combination NSCLC
JNJ-64457107 Anti- CD40 NCT02829099 (1) Monotherapy NSCLC/SCLC
Modified T cell therapy
TIL Tumor infiltrating lymphocytes NCT02133196 (2) Monotherapy NSCLC
DC-CTL Combined dendritic cells- cytotoxic t lymphocyte NCT02766348 (2) Monotherapy NSCLC
NCT02886897 (1/2) Combination NSCLC
IMMUNICELL® Autologous γδ- T lymphocytes NCT02459067 (2/3) Monotherapy NSCLC
MAGE A10c796T Chimeric antigen receptor T lymphocytes NCT02592577 (1/2) Monotherapy NSCLC
NY-ESO-1c259T NCT02588612 (1/2) Monotherapy NSCLC
ANTI-MUC1 CAR T NCT02587689 (1/2) Monotherapy NSCLC
PD1 knockout cells Modified T cell therapy NCT02793856 (1) Monotherapy NSCLC
Targeted NK cells Modified NK cell therapy NCT02118415 (2) Monotherapy NSCLC
NCT02845856 (1/2) Combination NSCLC
WT1-TCRC4-T cells WT1 targeted t cells NCT02408016 (1/2) Monotherapy NSCLC
rSIFN-co Recombinant interferon NCT02387307 (1) Monotherapy NSCLC
ALT-803 IL- 15 agonist NCT02523469 (1/2) Combination NSCLC
AM0010 Pegylated IL-10 NCT02009449 (1) Monotherapy NSCLC
AAT-007 Prostaglandin E receptor subtype 4 NCT02538432 (2) Monotherapy NSCLC
Poly-ICL Toll-like receptor agonist NCT02661100 (1/2) Combination NSCLC/SCLC
VTX-2337 NCT02650635 (1) Monotherapy NSCLC
L19-IL2 Antibody cytokine fusion protein NCT02735850 (2) Combination NSCLC
CDX-1401 DEC-205/NY-eso-1 fusion protein NCT02661100 (1/2) Combination NSCLC/SCLC
Targeted therapy EGFR inhibitors
ABBV-221 EGFR NCT02365662 (1) Monotherapy NSCLC
AC0010MA EGFR T790M NCT02448251 (1/2) Monotherapy NSCLC
Tesevatinib EGFR (CNS penetrant) NCT02616393 (2) Monotherapy NSCLC
JNJ-61186372 EGFR/MET bispecific mAb NCT02609776 (1) Monotherapy NSCLC
AP32788 EGFR exon 20 NCT02716116 (1/2) Monotherapy NSCLC
MM-151 and MM-121 EGFR mAb NCT02538627 (1) Monotherapy NSCLC
TargomiRs EGFR ab bound mir-16 NCT02369198 (1) Monotherapy NSCLC
Multi-kinase inhibitors
Navitoclax Bcl-2, Bcl-x, Bcl-w NCT02520778 (1) Combination NSCLC
CT-707 ALK, FAK, Pyk2 NCT02695550 (1) Monotherapy NSCLC
Famitinib c-Kit, VEGFR2, PDGFR, VEGFR3, FLT1, FLT3 NCT02356991 (2) Monotherapy NSCLC
NCT02364362 (1) Combination NSCLC
MGCD516 VEGFR, PDGFR, DDR2, TRK and Eph families NCT02219711 (1) Monotherapy NSCLC/SCLC
Pexidartinib Kit, FLT3, CAF1r NCT02452424 (1/2) Combination NSCLC
Anlotinib VEGF1/2/3, FGFR2 NCT02388919 (2/3) Monotherapy NSCLC
Entrectinib NTRK1/2/3, ROS1, ALK NCT02568267 (2) Monotherapy NSCLC
ASP2215 Axl, FLT3 NCT02495233 (1/2) Combination NSCLC/SCLC
PI3K/mTOR pathway inhibitors
MLN1117 PI3K NCT02393209 (1/2) Combination NSCLC
AZD8186 NCT01884285 (1) Monotherapy NSCLC
LY3023414 PI3K, mTOR NCT02443337 (2) Combination NSCLC
Other miscellaneous target inhibitors
LEE011 CDK 4/6 NCT02292550 (1/2) Combination NSCLC
Abemaciclib NCT02308020 (2) Monotherapy NSCLC
NCT02779751 (2) Monotherapy NSCLC
NCT02079636 (1) Combination NSCLC
INK128 TORC1/2 NCT02503722 (1) Combination NSCLC
Alisertib Aurora kinase inhibitor NCT01471964 (1/2) Combination NSCLC
Ibrutinib BTK NCT02321540 (1/2) Monotherapy NSCLC
TAK-659 Syk NCT02834247 (1) Combination NSCLC
Pyrotinib HER2 NCT02535507 (2) Monotherapy NSCLC
EphB4-HSA sEphB4 NCT02495896 (1) Combination NSCLC
Ficlatuzumab Hepatocyte growth factor (HGF) NCT02318368 (2) Combination NSCLC
AMG 479 IGFR-1 NCT01061788 (1) Combination NSCLC/SCLC
MM-121 HER3 NCT02387216 (2) Combination NSCLC
Defactinib Focal adhesion kinase (FAK) NCT02758587 (1/2) Combination NSCLC
JNJ-42756493 FGFR NCT02699606 (2) Monotherapy NSCLC
INCB054828 NCT02393248 (1/2) Monotherapy NSCLC/SCLC
LOXO-101 NTRK1/2/3 NCT02576431 (2) Monotherapy NSCLC/SCLC
RXDX-101 NCT02097810 (1) Monotherapy NSCLC/SCLC
Rh-endostatin NCT02375022 (2) Combination NSCLC
Cediranib NCT02498613 (2) Combination NSCLC/SCLC
GSK3052230 FGF ligand trap NCT01868022 (1) Combination NSCLC/SCLC
TRC105 Endoglin (CD105) NCT02429843 (1) Combination NSCLC
MEK162 MEK NCT01859026 (1) Combination NSCLC
PD-0325901 NCT02022982 (1/2) Combination NSCLC
Selumetinib RAS/RAF/MEK/ERK NCT01586624 (1) Combination NSCLC
Pacritnib JAK2 NCT02342353 (1/2) Monotherapy NSCLC
AT13387 Heat shock protein 90 NCT02535338 (1/2) Combination NSCLC
AUY922 NCT01922583 (2) Monotherapy NSCLC
NCT01854034 (2) Monotherapy NSCLC
Galunisertib TGFβ signaling NCT02423343 (1/2) Combination NSCLC/SCLC
MSC2156119J MET NCT01982955 (1/2) Combination NSCLC
Ralimetinib MAPK NCT02860780 (1) Combination NSCLC/SCLC
LTT462 NCT02711345 (1) Monotherapy NSCLC
PF-06671008 P-cadherin NCT02659631 (1) Monotherapy NSCLC/SCLC
BGB324 Axl NCT02424617 (1/2) Combination NSCLC
DNA repair VX790 ATR NCT02487095 (1/2) Combination SCLC
Veliparib PARP NCT01386385 (1/2) Combination NSCLC
Olaparib NCT02498613 (2) Combination NSCLC/SCLC
Chemotherapy Plinabulin Tubulin-depolymerization NCT02846792 (1/2) Combination NSCLC
NCT02812667 (1) Combination NSCLC
PT-112 Platinum based NCT02884479 (1/2) Combination NSCLC/SCLC
NC-6004 Micellar nanoparticle-encapsulated cisplatin NCT02240238 (1/2) Combination NSCLC
EC1456 Folic acid-tubulysin conjugate NCT01999738 (1) Monotherapy NSCLC/SCLC
Oncolytic virus CVA21 Coxsackievirus A21 NCT02043665 (1) Monotherapy NSCLC
NCT02824965 (1) Combination NSCLC
  1. ALK anaplastic lymphoma kinase, ATR ataxia telangiectasia and Rad3-related protein, AXL AXL receptor tyrosine kinase, BTK Bruton’s tyrosine kinase, CDK 4/6 cyclin-dependent kinase 4/6, CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1, dUTPase deoxyuridine triphophatase, FAK focal adhesion kinase, FGF fibroblast growth factor, FLT1/3 fms-like tyrosine kinase 1/3, c-Kit proto-oncogene c-Kit, Her2 human epidermal growth factor receptor 2, HLA human leukocyte antigen, IGFR insulin-like growth factor receptor, JAK2 Janus kinase 2, MAGEA3 melanoma-associated antigen 3, MAPK mitogen-activated protein kinase, MEK mitogen-activated protein kinase kinase, mTOR mammalian target of rapamycin, NTRK3 neurotrophic tyrosine kinase, PARP poly ADP ribose polymerase, PDGFR platelet-derived growth factor receptor, PI3K phosphatidylinositide 3-kinases, sEphB4 soluble extracellular domain of EphB4, Syk spleen tyrosine kinase, VEGFR vascular endothelial growth factor receptor, VISTA V-domain Ig suppressor of T cell activation, WT1 Wilms’ tumor protein